425 related articles for article (PubMed ID: 25935702)
1. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
2. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
3. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
4.
Kacew A; Sweis RF
Front Immunol; 2020; 11():575258. PubMed ID: 33224141
[No Abstract] [Full Text] [Related]
5. PD-L1 Antibody Comparison in Urothelial Carcinoma.
Rijnders M; van der Veldt AAM; Zuiverloon TCM; Grünberg K; Thunnissen E; de Wit R; van Leenders GJLH
Eur Urol; 2019 Mar; 75(3):538-540. PubMed ID: 30497882
[No Abstract] [Full Text] [Related]
6. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
[No Abstract] [Full Text] [Related]
7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of urothelial carcinoma.
Lopez-Beltran A; Cimadamore A; Montironi R; Cheng L
Hum Pathol; 2021 Jul; 113():67-83. PubMed ID: 33887300
[TBL] [Abstract][Full Text] [Related]
9. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
10. The Future of Precision Oncology for the Treatment of Solid Tumors.
Klute KA
Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
[No Abstract] [Full Text] [Related]
11. Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?
Zhu Z; Shen Z; Xu C
Anticancer Agents Med Chem; 2012 Nov; 12(9):1081-7. PubMed ID: 22583418
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathology in therapeutics: where are we now, and where are we going?
Harrison DJ; Faratian D
Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
[No Abstract] [Full Text] [Related]
14. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
15. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
16. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
18. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
19. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy.
Cimadamore A; Scarpelli M; Santoni M; Cheng L; Lopez-Beltran A; Montironi R
Expert Rev Mol Diagn; 2018 Dec; 18(12):1021-1028. PubMed ID: 30452305
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]